These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 31227343)
1. Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators. Winston-McPherson GN; Xie H; Yang K; Li X; Shu D; Tang W Bioorg Med Chem Lett; 2019 Aug; 29(16):2345-2348. PubMed ID: 31227343 [TBL] [Abstract][Full Text] [Related]
2. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove. Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094 [TBL] [Abstract][Full Text] [Related]
3. Small molecule modulators of PCSK9 - A literature and patent overview. Pettersen D; Fjellström O Bioorg Med Chem Lett; 2018 Apr; 28(7):1155-1160. PubMed ID: 29519739 [TBL] [Abstract][Full Text] [Related]
4. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol. Wang Y; Liu ZP Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249 [TBL] [Abstract][Full Text] [Related]
5. A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro. Li L; Shen C; Huang YX; Li YN; Liu XF; Liu XM; Liu JH Molecules; 2018 Sep; 23(9):. PubMed ID: 30235833 [TBL] [Abstract][Full Text] [Related]
6. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Seidah NG; Abifadel M; Prost S; Boileau C; Prat A Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219 [TBL] [Abstract][Full Text] [Related]
7. A review of PCSK9 inhibition and its effects beyond LDL receptors. Dixon DL; Trankle C; Buckley L; Parod E; Carbone S; Van Tassell BW; Abbate A J Clin Lipidol; 2016; 10(5):1073-80. PubMed ID: 27678423 [TBL] [Abstract][Full Text] [Related]
8. Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations. Guarnieri F; Kulp JL; Kulp JL; Cloudsdale IS PLoS One; 2019; 14(12):e0225780. PubMed ID: 31805108 [TBL] [Abstract][Full Text] [Related]
13. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor. Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction. Sun H; Wang J; Liu S; Zhou X; Dai L; Chen C; Xu Q; Wen X; Cheng K; Sun H; Yuan H J Chem Inf Model; 2021 Oct; 61(10):5269-5279. PubMed ID: 34553597 [TBL] [Abstract][Full Text] [Related]
15. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079 [TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332 [TBL] [Abstract][Full Text] [Related]